University of Groningenfounded in 1614  -  top 100 university
Close
About usHow to find usprof. dr. M.J. (Maarten) Postma

prof. dr. M.J. (Maarten) Postma

Professor Dept of Pharmacy & 2ndary appointment Professor UMCG

prof. dr. M.J. (Maarten) Postma
Telephone:
+31 50 36 37576 (secretary)
E-mail:
m.j.postma rug.nl

Research

Research units:

Advanced
Advanced

Reset

to
301 - 350 out of 699Page size: 50
  1. 2014
  2. van Boven, J. FM., Stuurman-Bieze, A. GG., Hiddink, E. G., Postma, M. J., & Vegter, S. (2014). Gerichte farmaceutische zorg voor patiënten met astma en COPD: een oriënterende studie. Pharmaceutisch Weekblad Wetenschappelijk Platform, 149(12), 49-53. [8:A1413].
  3. van Boven, J., Tommelein, E., Mehuys, E., Vegter, S., Brusselle, G. GO., Rutten-van Molken, M. P. M. H., & Postma, M. (2014). Het optimaliseren van de farmacotherapie bij patiënten met Chronisch Obstructief Longlijden (COPD) in de officina-apotheek: een kosten-effectiviteitsanalyse[1]. Farmaceutisch Tijdschrift voor België, 94(3), 15-16.
  4. Postma, M. (2014). Kosten van de zorg wegen we af tegen langer en/of aangenamer leven. In V. M. (Ed.), Gezonder ouder worden in Nederland (pp. 31-33). [Hoofdstuk 10] Breda: NPN Drukkers.
  5. Pechlivanoglou, P., Le, H. H., Daenen, S., Snowden, J. A., & Postma, M. J. (2014). Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: A systematic review. Journal of Antimicrobial Chemotherapy, 69(1), 1-11. https://doi.org/10.1093/jac/dkt329
  6. 2013
  7. Meijboom, M. J., Pouwels, K. B., Luytjes, W., Postma, M., & Hak, E. (2013). RSV vaccine in development: Assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine, 31(52), 6254-6260. https://doi.org/10.1016/j.vaccine.2013.10.023
  8. Van Boven, J. F. M., Vegter, S., Van Der Molen, T., & Postma, M. J. (2013). COPD in the working age population: The economic impact on both patients and government. COPD: Journal of Chronic Obstructive Pulmonary Disease, 10(6), 629-639. https://doi.org/10.3109/15412555.2013.813446
  9. Suwantika, A. A., & Postma, M. J. (2013). Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia. BMC Public Health, 13, [1106]. https://doi.org/10.1186/1471-2458-13-1106
  10. Mihajlovic, J., Pechlivanoglou, P., Sabo, A., Tomic, Z., & Postma, M. J. (2013). Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia. Clinical Therapeutics, 35(12), 1909-1922. https://doi.org/10.1016/j.clinthera.2013.10.004
  11. Suwantika, A. A., Yegenoglu, S., Riewpaiboon, A., Tu, H-A. T., & Postma, M. J. (2013). Economic evaluations of hepatitis A vaccination in middle-income countries. Expert review of vaccines, 12(12), 1479-1494. https://doi.org/10.1586/14760584.2013.851008
  12. van Boven, J. F. M., Hiddink, E. G., Stuurman-Bieze, A. G. G., Schuiling-Veninga, N., Postma, M., & Vegter, S. (2013). The pharmacists' potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma. International Journal of Clinical Pharmacy, 35(6), 1075-1082. https://doi.org/10.1007/s11096-013-9829-1
  13. Kotsopoulos, N., Connolly, M. P., Postma, M. J., & Hutubessy, R. C. W. (2013). Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine, 31(46), 5430-5434. https://doi.org/10.1016/j.vaccine.2013.09.002
  14. Mihajlović, J., Minović, I., Bruinsma, A., & Postma, M. J. (2013). Cost utility analysis of everolimus in the treatment of metastatic renal cell cancer in the Netherlands. Value in Health, 16(7), 416. https://doi.org/10.1016/j.jval.2013.08.534
  15. Vegter, S., Oosterhof, P., Van Boven, J. F., Stuurman-Bieze, A. G. G., Hiddink, E. G., & Postma, M. J. (2013). Cost-effectiveness of increasing statin adherence for primary and secondary prevention in community pharmacies. Value in Health, 16(7), 528. https://doi.org/10.1016/j.jval.2013.08.1295
  16. Vemer, P., & Postma, M. J. (2013). Cost-effectiveness of infant pneumococcal vaccination in the Netherlands. Value in Health, 16(7), 334. https://doi.org/10.1016/j.jval.2013.08.073
  17. De Boer, P. T., & Postma, M. J. (2013). Cost-effectiveness of universal vaccination ag ainst varicella in the Netherlands. Value in Health, 16(7), A357. https://doi.org/10.1016/j.jval.2013.08.203
  18. Stevanovic, J., Pompen, M., Le, H. H., Rozenbaum, M. H., & Postma, M. J. (2013). Economic evaluation of apixaban for the prevention of stroke in atrial fibrillation in the Netherlands. Value in Health, 16(7), A529-530. https://doi.org/10.1016/j.jval.2013.08.1303
  19. De Vries, F. M., Denig, P., Vegter, S., Bos, H. J., Postma, M. J., & Hak, E. (2013). Effects of the occurrence of a first cardiovascular event on statin adherence in type 2 diabetes: A matched cohort design. Value in Health, 16(7), 532-533. https://doi.org/10.1016/j.jval.2013.08.1320
  20. Le, H. H., Pechlivanoglou, P., & Postma, M. J. (2013). Indirect treatment comparison and economic evaluation of novel oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in the Netherlands. Value in Health, 16(7), A514. https://doi.org/10.1016/j.jval.2013.08.1213
  21. Sinclair, M., Lis, Y., Van Engen, A., Van Ganse, E., Autier, P., Daumer, M., ... Prieto, L. (2013). Introducing the encepp working group (WG) on health technology assessment (HTA): Enhancing the generation of additional evidence for HTA processes. Value in Health, 16(7), A491. https://doi.org/10.1016/j.jval.2013.08.977
  22. Jiang, Y., Gauthier, A., Postma, M. J., Ribassin-Majed, L., Largeron, N., & Bresse, X. (2013). A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus. Human vaccines & immunotherapeutics, 9(11), 2285-2295. https://doi.org/10.4161/hv.25754
  23. De Vries, F. M., Denig, P., Visser, S. T., Hak, E., & Postma, M. J. (2013). Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients: An illustration for The Netherlands. Pharmacoepidemiology and Drug Safety, 22(s1), 117-118.
  24. van Hasselt, F. M., Krabbe, P. F. M., van Ittersum, D. G., Postma, M. J., & Loonen, A. J. M. (2013). Evaluating interventions to improve somatic health in severe mental illness: A systematic review. Acta Psychiatrica Scandinavica, 128(4), 251-260. https://doi.org/10.1111/acps.12096
  25. Mapako, T., Mvere, D. A., Chitiyo, M. E., Rusakaniko, S., Postma, M. J., & Van Hulst, M. (2013). Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety. Transfusion, 53(10 pt 2), 2413-2421. https://doi.org/10.1111/trf.12311
  26. Xiridou, M., Vriend, H. J., Lugner, A. K., Wallinga, J., Fennema, J. S., Prins, J. M., ... van der Sande, M. A. B. (2013). Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men. BMC Infectious Diseases, 13(1), [436]. https://doi.org/10.1186/1471-2334-13-436
  27. Vriend, H. J., Lugnér, A. K., Xiridou, M., Van Der Loeff, M. F. S., Prins, M., De Vries, H. J. C., ... Van Der Sande, M. A. B. (2013). Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective. Aids, 27(14), 2281-2290. https://doi.org/10.1097/QAD.0b013e32836281ee
  28. van Boven, J. F. M., de Boer, P. T., Postma, M. J., & Vegter, S. (2013). Persistence with osteoporosis medication among newly-treated osteoporotic patients. Journal of bone and mineral metabolism, 31(5), 562-570. https://doi.org/10.1007/s00774-013-0440-2
  29. Urbanus, A. T., van Keep, M., Matser, A. A., Rozenbaum, M. H., Weegink, C. J., van den Hoek, A., ... Postma, M. J. (2013). Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS ONE, 8(8), [e70319]. https://doi.org/10.1371/journal.pone.0070319
  30. Parouty, M. B. Y., Krooshof, D. G. M., Westra, T. A., Pechlivanoglou, P., & Postma, M. J. (2013). Reviewing and piloting methods for decreasing discount rates; someone, somewhere in time. Expert review of pharmacoeconomics & outcomes research, 13(4), 523-547. https://doi.org/10.1586/14737167.2013.815404
  31. Suwantika, A. A., Tu, H. A. T., & Postma, M. J. (2013). Cost-effectiveness of rotavirus immunization in Indonesia: Taking breastfeeding patterns into account. Vaccine, 31(32), 3300-3307. https://doi.org/10.1016/j.vaccine.2013.04.055
  32. Gefenaite, G., Tacken, M., Bos, J., Stirbu-Wagner, I., Korevaar, J. C., Stolk, R. P., ... Hak, E. (2013). Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination. PLoS ONE, 8(6), [e66125]. https://doi.org/10.1371/journal.pone.0066125
  33. Mafirakureva, N., Khoza, S., Van Hulst, M., Postma, M. J., & Mvere, D. A. (2013). The evaluation of blood donor deferral causes in Zimbabwe. Vox Sanguinis, 105, 97. https://doi.org/10.1111/vox.12048
  34. Visser, S. T., Schuiling-Veninga, N., Bos, J. H. J., de Jong-van den Berg, L. T. W., & Postma, M. J. (2013). The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert review of pharmacoeconomics & outcomes research, 13(3), 285-292. https://doi.org/10.1586/erp.13.20
  35. Hepkema, H., Pouwels, K. B., van der Ende, A., Westra, T. A., & Postma, M. J. (2013). Meningococcal Serogroup A, C, W-135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands. PLoS ONE, 8(5), [e65036]. https://doi.org/10.1371/journal.pone.0065036
  36. Postma, M. J., & Standaert, B. A. (2013). Economics of vaccines revisited. Human vaccines & immunotherapeutics, 9(5), 1139-1141. https://doi.org/10.4161/hv.23447
  37. Pouwels, K. B., Hak, E., Van Der Ende, A., Christensen, H., Van Den Dobbelsteen, G. P. J. M., & Postma, M. J. (2013). Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Human vaccines & immunotherapeutics, 9(5), 1129-1138. https://doi.org/10.4161/hv.23888
  38. Postma, M. J., Westra, T. A., Quilici, S., & Largeron, N. (2013). Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples. Expert review of vaccines, 12(5), 555-565. https://doi.org/10.1586/erv.13.36
  39. Rozenbaum, M. H., & Postma, M. J. (2013). Response on "RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands". Vaccine, 31(16), 2024. https://doi.org/10.1016/j.vaccine.2012.11.082
  40. Kelso, J. K., Halder, N., Postma, M. J., & Milne, G. J. (2013). Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories. BMC Public Health, 13, [211]. https://doi.org/10.1186/1471-2458-13-211
  41. Van Hasselt, F. M., Krabbe, P. F. M., Postma, M. J., & Loonen, A. J. M. (2013). Evaluation of interventions to improve somatic health in severe mental illness: A conceptual framework. Journal of Mental Health Policy and Economics, 16, 37.
  42. Kotsopoulos, N., Connolly, M. P., Sobanski, E., & Postma, M. J. (2013). The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. Journal of Mental Health Policy and Economics, 16(1), 27-33.
  43. Rozenbaum, M. H., Pechlivanoglou, P., Van Der Werf, T. S., Lo-Ten-Foe, J. R., Postma, M. J., & Hak, E. (2013). The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases, 32(3), 305-316. https://doi.org/10.1007/s10096-012-1778-4
  44. de Boer, P. T., Pouwels, K. B., Cox, J. M., Hak, E., Wilschut, J. C., & Postma, M. J. (2013). Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine, 31(9), 1276-1283. https://doi.org/10.1016/j.vaccine.2012.12.067
  45. Westra, T. A., Stirbu-Wagner, I., Dorsman, S., Tutuhatunewa, E. D., de Vrij, E. L., Nijman, H. W., ... Postma, M. J. (2013). Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infectious Diseases, 13(1), [75]. https://doi.org/10.1186/1471-2334-13-75
  46. Connolly, M., Kuyvenhoven, J., Postma, M., & Nielsen, S. (2013). The economics of 4 grams once daily mesalazine dosing compared with 4 grams twice daily in active ulcerative colitis. Journal of Crohn's and Colitis, 7(P353), S151. https://doi.org/10.1016/S1873-9946(13)60374-8
  47. Tu, H. A. T., Rozenbaum, M. H., de Boer, P. T., Noort, A. C., & Postma, M. J. (2013). An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model". BMC Infectious Diseases, 13(1), [54]. https://doi.org/10.1186/1471-2334-13-54
  48. Bakir, M., Standaert, B., Turel, O., Bilge, Z. E., & Postma, M. (2013). Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine, 31(6), 979-986. https://doi.org/10.1016/j.vaccine.2012.11.071
  49. Standaert, B., Gomez, J. A., Raes, M., Debrus, S., Raul Velazquez, F., & Postma, M. J. (2013). Impact of Rotavirus Vaccination on Hospitalisations in Belgium: Comparing Model Predictions with Observed Data. PLoS ONE, 8(1), [e53864]. https://doi.org/10.1371/journal.pone.0053864
  50. Mihajlovic, J., Pechlivanoglou, P., Miladinov-Mikov, M., Zivković, S., & Postma, M. J. (2013). Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer, 13, [18]. https://doi.org/10.1186/1471-2407-13-18
  51. Postma, M. J., Kappelhoff, B. S., Van Hulst, M., & Brouwers, J. R. B. J. (2013). Author response to letter to the editor. Journal of Medical Economics, 16(3), 372-373. https://doi.org/10.3111/13696998.2012.759581
  52. Postma, M. J., Parouty, M., & Westra, T. A. (2013). Accumulating evidence for the case of differential discounting. Expert Review of Clinical Pharmacology, 6(1), 1-3. https://doi.org/10.1586/ecp.12.73
Previous 1...3 4 5 6 7 8 9 10 ...14 Next

ID: 193217

University of Groningen staff: edit these data

print
Follow the UGfacebook twitter linkedin rss instagram youtube